Cargando…

Qishenyiqi Protects Ligation-Induced Left Ventricular Remodeling by Attenuating Inflammation and Fibrosis via STAT3 and NF-κB Signaling Pathway

AIM: Qi-shen-yi-qi (QSYQ), a formula used for the routine treatment of heart failure (HF) in China, has been demonstrated to improve cardiac function through down-regulating the activation of the Renin-Angiotensin-Aldosterone System (RAAS). However, the mechanisms governing its therapeutic effects a...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chun, Wang, Yong, Qiu, Qi, Shi, Tianjiao, Wu, Yan, Han, Jing, Chai, Xingyun, Wang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133204/
https://www.ncbi.nlm.nih.gov/pubmed/25122164
http://dx.doi.org/10.1371/journal.pone.0104255
_version_ 1782330728988540928
author Li, Chun
Wang, Yong
Qiu, Qi
Shi, Tianjiao
Wu, Yan
Han, Jing
Chai, Xingyun
Wang, Wei
author_facet Li, Chun
Wang, Yong
Qiu, Qi
Shi, Tianjiao
Wu, Yan
Han, Jing
Chai, Xingyun
Wang, Wei
author_sort Li, Chun
collection PubMed
description AIM: Qi-shen-yi-qi (QSYQ), a formula used for the routine treatment of heart failure (HF) in China, has been demonstrated to improve cardiac function through down-regulating the activation of the Renin-Angiotensin-Aldosterone System (RAAS). However, the mechanisms governing its therapeutic effects are largely unknown. The present study aims to demonstrate that QSYQ treatment can prevent left ventricular remodeling in heart failure by attenuating oxidative stress and inhabiting inflammation. METHODS: Sprague-Dawley (SD) rats were randomly divided into 6 groups: sham group, model group (LAD coronary artery ligation), QSYQ group with high dosage, middle dosage and low dosage (LAD ligation and treated with QSYQ), and captopril group (LAD ligation and treated with captopril as the positive drug). Indicators of fibrosis (Masson, MMPs, and collagens) and inflammation factors were detected 28 days after surgery. RESULTS: Results of hemodynamic alterations (dp/dt value) in the model group as well as other ventricular remodeling (VR) markers, such as MMP-2, MMP-9, collagen I and III elevated compared with sham group. VR was accompanied by activation of RAAS (angiotensin II and NADPHoxidase). Levels of pro-inflammatory cytokines (TNF-α, IL-6) in myocardial tissue were also up-regulated. Treatment of QSYQ improved cardiac remodeling through counter-acting the aforementioned events. The improvement of QSYQ was accompanied with a restoration of angiotensin II-NADPHoxidase-ROS-MMPs pathways. In addition, “therapeutic” QSYQ administration can reduce both TNF-α-NF-B and IL-6-STAT3 pathways, respectively, which further proves the beneficial effects of QSYQ. CONCLUSIONS: Our study demonstrated that QSYQ protected LAD ligation-induced left VR via attenuating AngII -NADPH oxidase pathway and inhabiting inflammation. These findings provide evidence as to the cardiac protective efficacy of QSYQ to HF and explain the beneficial effects of QSYQ in the clinical application for HF.
format Online
Article
Text
id pubmed-4133204
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-41332042014-08-19 Qishenyiqi Protects Ligation-Induced Left Ventricular Remodeling by Attenuating Inflammation and Fibrosis via STAT3 and NF-κB Signaling Pathway Li, Chun Wang, Yong Qiu, Qi Shi, Tianjiao Wu, Yan Han, Jing Chai, Xingyun Wang, Wei PLoS One Research Article AIM: Qi-shen-yi-qi (QSYQ), a formula used for the routine treatment of heart failure (HF) in China, has been demonstrated to improve cardiac function through down-regulating the activation of the Renin-Angiotensin-Aldosterone System (RAAS). However, the mechanisms governing its therapeutic effects are largely unknown. The present study aims to demonstrate that QSYQ treatment can prevent left ventricular remodeling in heart failure by attenuating oxidative stress and inhabiting inflammation. METHODS: Sprague-Dawley (SD) rats were randomly divided into 6 groups: sham group, model group (LAD coronary artery ligation), QSYQ group with high dosage, middle dosage and low dosage (LAD ligation and treated with QSYQ), and captopril group (LAD ligation and treated with captopril as the positive drug). Indicators of fibrosis (Masson, MMPs, and collagens) and inflammation factors were detected 28 days after surgery. RESULTS: Results of hemodynamic alterations (dp/dt value) in the model group as well as other ventricular remodeling (VR) markers, such as MMP-2, MMP-9, collagen I and III elevated compared with sham group. VR was accompanied by activation of RAAS (angiotensin II and NADPHoxidase). Levels of pro-inflammatory cytokines (TNF-α, IL-6) in myocardial tissue were also up-regulated. Treatment of QSYQ improved cardiac remodeling through counter-acting the aforementioned events. The improvement of QSYQ was accompanied with a restoration of angiotensin II-NADPHoxidase-ROS-MMPs pathways. In addition, “therapeutic” QSYQ administration can reduce both TNF-α-NF-B and IL-6-STAT3 pathways, respectively, which further proves the beneficial effects of QSYQ. CONCLUSIONS: Our study demonstrated that QSYQ protected LAD ligation-induced left VR via attenuating AngII -NADPH oxidase pathway and inhabiting inflammation. These findings provide evidence as to the cardiac protective efficacy of QSYQ to HF and explain the beneficial effects of QSYQ in the clinical application for HF. Public Library of Science 2014-08-14 /pmc/articles/PMC4133204/ /pubmed/25122164 http://dx.doi.org/10.1371/journal.pone.0104255 Text en © 2014 Li et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Li, Chun
Wang, Yong
Qiu, Qi
Shi, Tianjiao
Wu, Yan
Han, Jing
Chai, Xingyun
Wang, Wei
Qishenyiqi Protects Ligation-Induced Left Ventricular Remodeling by Attenuating Inflammation and Fibrosis via STAT3 and NF-κB Signaling Pathway
title Qishenyiqi Protects Ligation-Induced Left Ventricular Remodeling by Attenuating Inflammation and Fibrosis via STAT3 and NF-κB Signaling Pathway
title_full Qishenyiqi Protects Ligation-Induced Left Ventricular Remodeling by Attenuating Inflammation and Fibrosis via STAT3 and NF-κB Signaling Pathway
title_fullStr Qishenyiqi Protects Ligation-Induced Left Ventricular Remodeling by Attenuating Inflammation and Fibrosis via STAT3 and NF-κB Signaling Pathway
title_full_unstemmed Qishenyiqi Protects Ligation-Induced Left Ventricular Remodeling by Attenuating Inflammation and Fibrosis via STAT3 and NF-κB Signaling Pathway
title_short Qishenyiqi Protects Ligation-Induced Left Ventricular Remodeling by Attenuating Inflammation and Fibrosis via STAT3 and NF-κB Signaling Pathway
title_sort qishenyiqi protects ligation-induced left ventricular remodeling by attenuating inflammation and fibrosis via stat3 and nf-κb signaling pathway
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133204/
https://www.ncbi.nlm.nih.gov/pubmed/25122164
http://dx.doi.org/10.1371/journal.pone.0104255
work_keys_str_mv AT lichun qishenyiqiprotectsligationinducedleftventricularremodelingbyattenuatinginflammationandfibrosisviastat3andnfkbsignalingpathway
AT wangyong qishenyiqiprotectsligationinducedleftventricularremodelingbyattenuatinginflammationandfibrosisviastat3andnfkbsignalingpathway
AT qiuqi qishenyiqiprotectsligationinducedleftventricularremodelingbyattenuatinginflammationandfibrosisviastat3andnfkbsignalingpathway
AT shitianjiao qishenyiqiprotectsligationinducedleftventricularremodelingbyattenuatinginflammationandfibrosisviastat3andnfkbsignalingpathway
AT wuyan qishenyiqiprotectsligationinducedleftventricularremodelingbyattenuatinginflammationandfibrosisviastat3andnfkbsignalingpathway
AT hanjing qishenyiqiprotectsligationinducedleftventricularremodelingbyattenuatinginflammationandfibrosisviastat3andnfkbsignalingpathway
AT chaixingyun qishenyiqiprotectsligationinducedleftventricularremodelingbyattenuatinginflammationandfibrosisviastat3andnfkbsignalingpathway
AT wangwei qishenyiqiprotectsligationinducedleftventricularremodelingbyattenuatinginflammationandfibrosisviastat3andnfkbsignalingpathway